Dermata Therapeutics, Inc.
DRMA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $207 | $178 | $6,780 | $21,737 |
| - Cash | $3,162 | $7,438 | $6,241 | $10,799 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | -$2,955 | -$7,261 | $538 | $10,939 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$12,287 | $247 | -$9,611 | -$7,857 |
| % Margin | – | – | – | – |
| Net Income | -$12,287 | -$7,795 | -$9,611 | -$7,902 |
| % Margin | – | – | – | – |
| EPS Diluted | -80.32 | -399.81 | -139.2 | -152.7 |
| % Growth | 79.9% | -187.2% | 8.8% | – |
| Operating Cash Flow | -$11,163 | -$6,409 | -$8,834 | -$5,693 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$11,163 | -$6,409 | -$8,834 | -$5,693 |